Skip to main content

Advertisement

Log in

Improved kinetic stability of DTPA-dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

The development of monofunctional DTPA derivatives has been a major breakthrough in the labelling of proteins or peptides with a variety of radiometals. Although this methodology is simple and useful for indium-111 labelling, the stability of these conjugates is too low for most therapeutic nuclides. Cyclic chelators, such as DOTA, have shown excellent kinetic stability with a variety of radiometals, but the labelling procedure is more difficult, requiring ultra-pure reagents and a heating step that sometimes endangers the biomolecule's integrity. The aim of this work was twofold: (a) to develop a novel, open chain chelator which can be easily labelled with various radiometals, displaying higher kinetic stability than monofunctional DTPA, and (b) to evaluate this chelator in vitro and in vivo when conjugated to a CCK-B receptor ligand as a detection modality for receptor-(over-)expressing tumours. DTPA derivatives of Leu1- and dGlu1-minigastrin were synthesised. All conjugates could be labelled with 111In or 88/90Y at high specific activities (8.5–44.4 GBq/μmol) and with high radiochemical purity. Serum stability testing was performed, and the labelled conjugates were compared concerning their stability against DTPA challenge. The biodistribution of the radiolabelled Leu1- and dGlu1-minigastrin derivatives was studied in tumour-bearing nude mice, in one healthy human volunteer and in three patients with metastatic medullary thyroid carcinoma. The transchelation of all tested radiometals to serum proteins was significantly slower with the DTPA-Glu conjugates as compared with their Leu analogues (e.g. transchelation t 1/2 of DTPA-dGlu1-minigastrin vs its Leu1 analogue at 37°C in human serum for 111In: 239 h vs 91 h; for 90Y: 130 h vs 53 h). In animals, all labelled CCK-B receptor ligands showed fast and specific uptake in CCK-B-receptor-positive tissues, such as the stomach and tumour, as well as a fast renal clearance pattern. However, DTPA-Leu1-minigastrin showed higher background activity in the whole body and those organs known to accumulate the respective free radiometal (e.g. 88Y-DTPA-Leu1-minigastrin had bone uptake of 22%ID/g as compared to only 1.2%ID/g with its dGlu1 analogue). In humans, fast tumour and stomach uptake was observed for both 111In-labelled compounds, but DTPA-dGlu1-minigastrin lacked the liver, spleen and bone marrow uptake observed with its Leu1 analogue. In conclusion, anionic amino acid derivatives of DTPA may display improved metabolic stability as compared with monofunctional DTPA conjugates. DTPA-dGlu1-minigastrin is preferred to "monofunctional" DTPA-Leu1-minigastrin for diagnostic application with 111In for the in vivo detection of CCK-B receptor-expressing tissues.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.
Fig. 3.

Similar content being viewed by others

References

  1. Signore A, Annovazzi A, Chianelli M, et al. Peptide radiopharmaceuticals for diagnosis and therapy. Eur J Nucl Med 2001; 28:1555–1565.

    Google Scholar 

  2. Behr TM, Behe M, Becker W. Diagnostic applications of radiolabeled peptides in nuclear endocrinology. Q J Nucl Med 1999; 43:268–280.

    Google Scholar 

  3. Reubi JC. The role of peptides and their receptors as tumor markers. Endocrinol Metab Clin North Am 1993; 22:917–939.

    CAS  PubMed  Google Scholar 

  4. Bakker WH, Krenning EP, Breeman WA, et al. Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabeling, purification, biologic activity, and in vivo application in animals. J Nucl Med 1990; 31:1501–1509.

    CAS  PubMed  Google Scholar 

  5. Krenning EP, Bakker WH, Kooij PP, et al. Somatostatin receptor scintigraphy with indium-111-DTPA-d-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med 1992; 33:652–658.

    CAS  PubMed  Google Scholar 

  6. Hnatowich DJ, Layne WW, Childs RL, et al. Radioactive labeling of antibody: a simple and efficient method. Science 1983; 220:613–615.

    CAS  PubMed  Google Scholar 

  7. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20:716–731.

    CAS  PubMed  Google Scholar 

  8. Lamberts SW, Hofland LJ, van Koetsveld PM, et al. Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localization, and therapy. J Clin Endocrinol Metab 1990; 71:566–574.

    CAS  PubMed  Google Scholar 

  9. Stolz B, Smith-Jones P, Albert R, et al. Somatostatin analogues for somatostatin-receptor-mediated radiotherapy of cancer. Digestion 1996; 57 Suppl 1:17–21.

    Google Scholar 

  10. Heppeler A, Froidevaux S, Eberle AN, et al. Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem 2000; 7:971–994.

    CAS  PubMed  Google Scholar 

  11. Stolz B, Weckbecker G, Smith-Jones PM, et al. The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-dPhe1, Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours. Eur J Nucl Med 1998; 25:668–674.

    Google Scholar 

  12. Otte A, Mueller-Brand J, Dellas S, et al. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 1998; 351:417–418.

    CAS  PubMed  Google Scholar 

  13. Henze M, Schuhmacher J, Hipp P, et al. PET imaging of somatostatin receptors using. J Nucl Med 2001; 42:1053–1056.

    CAS  PubMed  Google Scholar 

  14. Reubi JC, Waser B. Unexpected high incidence of cholecystokinin-B/gastrin receptors in human medullary thyroid carcinomas. Int J Cancer 1996; 67:644–647.

    Article  CAS  PubMed  Google Scholar 

  15. Reubi JC, Schaer JC, Waser B. Cholecystokinin (CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res 1997; 57:1377–1386.

    CAS  PubMed  Google Scholar 

  16. Wank SA, Pisegna JR, de Weerth A. Cholecystokinin receptor family. Molecular cloning, structure, and functional expression in rat, guinea pig, and human. Ann N Y Acad Sci 1994; 713:49–66.

    CAS  PubMed  Google Scholar 

  17. Behr TM, Jenner N, Radetzky S, et al. Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. Eur J Nucl Med 1998; 25:424–430.

    Article  CAS  PubMed  Google Scholar 

  18. de Jong M, Bakker WH, Bernard BF, et al. Preclinical and initial clinical evaluation of111In-labeled nonsulfated CCK8 analog: a peptide for CCK-B receptor-targeted scintigraphy and radionuclide therapy. J Nucl Med 1999; 40:2081–2087.

    PubMed  Google Scholar 

  19. Behr TM, Jenner N, Behe M, et al. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors. J Nucl Med 1999; 40:1029–1044.

    CAS  PubMed  Google Scholar 

  20. Bakker WH, Albert R, Bruns C, et al. [111In-DTPA-d-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation. Life Sci 1991; 49:1583–1591.

    CAS  PubMed  Google Scholar 

  21. Otte A, Jermann E, Behe M, et al. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 1997; 24:792–795.

    Google Scholar 

  22. Virgolini I, Patri P, Novotny C, et al. Comparative somatostatin receptor scintigraphy using In-111-DOTA-lanreotide and In-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy. Ann Oncol 2001; 12 Suppl 2:S41–S45.

  23. Smith-Jones PM, Bischof C, Leimer M, et al. DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy. Endocrinology 1999; 140:5136–5148.

    CAS  PubMed  Google Scholar 

  24. Heppeler A, Froidevaux S, Macke HR, et al. Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy. Chemistry—A European Journal 1999; 5:1974–1981.

    Google Scholar 

  25. Nakata H, Wang SL, Chung DC, et al. Oncogenic ras induces gastrin gene expression in colon cancer. Gastroenterology 1998; 115:1144–1153.

    CAS  PubMed  Google Scholar 

  26. Clerc P, Dufresne M, Saillan C, et al. Differential expression of the CCK-A and CCK-B/gastrin receptor genes in human cancers of the esophagus, stomach and colon. Int J Cancer 1997; 72:931–936.

    PubMed  Google Scholar 

  27. Okada N, Kubota A, Imamura T, et al. Evaluation of cholecystokinin, gastrin, CCK-A receptor, and CCK-B/gastrin receptor gene expressions in gastric cancer. Cancer Lett 1996; 106:257–262.

    CAS  PubMed  Google Scholar 

  28. Upp JR Jr, Singh P, Townsend CM Jr, et al. Clinical significance of gastrin receptors in human colon cancers. Cancer Res 1989; 49:488–492.

    PubMed  Google Scholar 

  29. Reubi JC, Waser B, Laderach U, et al. Localization of cholecystokinin A and cholecystokinin B-gastrin receptors in the human stomach. Gastroenterology 1997; 112:1197–1205.

    CAS  PubMed  Google Scholar 

  30. Behr TM, Behe M, Angerstein C, et al. Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential. Clin Cancer Res 1999; 5:3124s–3138s.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Martin Béhé.

Additional information

Wolfgang Becker has died since the completion of this article.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Béhé, M., Becker, W., Gotthardt, M. et al. Improved kinetic stability of DTPA-dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives. Eur J Nucl Med Mol Imaging 30, 1140–1146 (2003). https://doi.org/10.1007/s00259-003-1178-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-003-1178-1

Keywords

Navigation